Understanding how other nasal peptide products perform provides useful context for setting realistic expectations
speaker for Mitsubishi Tanabe Pharma Corporation, NAPP and Takeda Pharmaceuticals International Inc
We are grateful for the assistance of the Core Laboratories at School of Biomedical Sciences, the Chinese University of Hong Kong, and Histomorphometry and Molecular Analysis Core at the University of Alabama at Birmingham
Factors to consider include the severity of maternal diabetes or obesity, availability of alternative treatments, the infant's age and health status, and whether breastfeeding is exclusive or supplemented with formula
Topical makes the most sense for: Facial skin texture, fine lines, hydration Scalp application for localized hair growth Scar treatment or post-procedure recovery on a specific area Patients who want to fold GHK-Cu into an existing skincare routine Injectable makes the most sense for: Systemic wound healing (especially internal or in areas you can't easily apply cream) Joint and connective tissue support (topical simply can't penetrate deep enough) Broader anti-aging goals beyond the skin surface Patients already running other injectable peptide protocols (CJC-1295/ipamorelin, BPC-157, TB-500) Here's the thing: for joints specifically, there's no argument
Journal of Physiology-Paris , 91, 173-178
